INTERNATIONAL PATENT: ORIC PHARMACEUTICALS, INC., DANA-FARBER CANCER INSTITUTE, INC. FILES APPLICATION FOR "CD73 INHIBITOR AND ANTI-CD38 AGENT COMBINATION THERAPY"

GENEVA, May 14 -- ORIC PHARMACEUTICALS, INC. (240 E. Grand Avenue, 2nd FloorSouth San Francisco, California 94080), DANA-FARBER CANCER INSTITUTE, INC. (450 Brookline AvenueBoston, Massachusetts 02215) filed a patent application (PCT/US2024/053652) for "CD73 INHIBITOR AND ANTI-CD38 AGENT COMBINATION THERAPY" on Oct 30, 2024. With publication no. WO/2025/096605, the details related to the patent application was published on May 08, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): JUNTTILA, Melissa R. (240 E. Grand Avenue, 2nd FloorSouth San Francisco, California 94080), FRIEDMAN, Lori S. (240 E...